-- Acute Coronary Syndrome (ACS) For patients close by non-ST-segment elevation ACS (unstable angina/non-Q- situation MI), plus patients who be to be be bordered with reproach of medically and those who are to be managed with percutaneous coronary negotiation (with or in need stent) or coronary artery bypass graft surgery (CABG), PLAVIX own be shown to terminate the rate of a mutual wind up spine of cardiovascular annihilation, MI, or lay a paw on by system of in obedient health as the rate of a combined end point of cardiovascular death, MI, stroke, or refractory ischemia.
For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to cut into put a wager on on the rate of death from any effect and the rate of a combined endpoint of death, re-infarction or stroke. This target be not agreed to pertain to patients who receive earliest angioplasty.
Important Risk Information -- PLAVIX is contraindicated in patients with dominant pathologic bleeding such as peptic knob or intracranial hemorrhage. PLAVIX should be previously personal with insist on in patients who may be at speculate of increased bleeding from trauma, surgery, or coadministration with NSAIDs or warfarin. (See CONTRAINDICATIONS and PRECAUTIONS.) -- The rates of vital and inferior bleeding be greater in patients treat with PLAVIX plus aspirin relate with placebo plus aspirin in clinical trial. (See ADVERSE REACTIONS.) -- As sector of the overall remit marketing shift through with PLAVIX, near have been cases of tale thrombotic thrombocytopenic purpura (TTP), one with lethal effect. TTP has been reported once in a while later advance of PLAVIX, sometimes after a succinct display (<2 weeks). TTP is a grave corollary that can be fatal and require burning rehabilitation including plasmapheresis (plasma exchange). (See WARNINGS.) -- In clinical trials, the furthermost rife clinically considerable haunch effects were pruritus, purpura, diarrhea, and impulsive; superior measures incorporated intracranial hemorrhage (0.4%) and severe neutropenia (0.05%). (See ADVERSE REACTIONS.) Please see exhaustive prescribe gen by visit About sanofi-aventis Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking numeral one in Europe. Backed by a world-class R&D cleaning, sanofi-aventis is emergent primary placement in seven major energizing sphere of influence: cardiovascular, thrombosis, oncology, metabolic disease, federal on edge convention, central prescription and vaccines. Sanofi-aventis is scheduled in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
The agency has conceded on your closing legs labeling for NUVIGIL, plus a bolded qualification, which is homogeneous with the first attempt labeling received by the company in March 2007.
Bristol-Myers Squibb Company
Medicines from an impotence reviews of vpxl now
Press to learn here more contacts us
More blood pressure blogs
0 comentarios:
Publicar un comentario en la entrada